JIANGXI SYNERGY PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.32 CNY | +3.30% |
|
-3.28% | -2.09% |
| 06-24 | Jiangxi Synergy Pharmaceutical Co., Ltd.(XSEC:300636) dropped from S&P Global BMI Index | CI |
| 05-20 | Jiangxi Synergy Pharmaceutical Co., Ltd. Approves Board Appointments | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,898 | 5,427 | 5,134 | 4,423 | 4,176 | - | - |
| Enterprise Value (EV) 1 | 2,898 | 5,427 | 5,134 | 4,423 | 4,176 | 4,176 | 4,176 |
| P/E ratio | 40.2 x | 73.1 x | 50.9 x | 37.8 x | 24.6 x | 21.1 x | 12.4 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 7.13 x | 6.12 x | 4.63 x | 3.62 x | - |
| EV / Revenue | - | - | 7.13 x | 6.12 x | 4.63 x | 3.62 x | - |
| EV / EBITDA | - | - | 29.8 x | 24.5 x | 16 x | 12.7 x | - |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | - | - | 3.93 x | 2 x | 1.9 x | 1.79 x | - |
| Nbr of stocks (in thousands) | 308,688 | 308,796 | 346,665 | 419,611 | 418,002 | - | - |
| Reference price 2 | 9.388 | 17.57 | 14.81 | 10.54 | 10.32 | 10.32 | 10.32 |
| Announcement Date | 21-01-14 | 22-04-22 | 23-04-23 | 24-04-24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 719.9 | 722.1 | 902 | 1,153 | - |
| EBITDA 1 | - | - | 172.4 | 180.8 | 261 | 330 | - |
| EBIT 1 | - | - | 106.3 | 112.2 | 135 | 177 | - |
| Operating Margin | - | - | 14.77% | 15.54% | 14.97% | 15.35% | - |
| Earnings before Tax (EBT) 1 | - | - | 106.1 | 112.5 | 135 | 176 | - |
| Net income 1 | 72.17 | 81.12 | 100.7 | 106 | 179 | 207.5 | 353 |
| Net margin | - | - | 13.98% | 14.68% | 19.84% | 18% | - |
| EPS 2 | 0.2338 | 0.2403 | 0.2908 | 0.2786 | 0.4200 | 0.4900 | 0.8300 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 21-01-14 | 22-04-22 | 23-04-23 | 24-04-24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | 9.18% | 6.06% | 5.5% | 6.7% | - |
| ROA (Net income/ Total Assets) | - | - | - | 3.87% | 3.8% | 4.7% | - |
| Assets 1 | - | - | - | 2,740 | 4,711 | 4,415 | - |
| Book Value Per Share 2 | - | - | 3.770 | 5.260 | 5.440 | 5.780 | - |
| Cash Flow per Share | - | - | 0.5600 | 0.3900 | - | - | - |
| Capex 1 | - | - | 310 | 214 | 274 | 236 | - |
| Capex / Sales | - | - | 43.11% | 29.69% | 30.38% | 20.47% | - |
| Announcement Date | 21-01-14 | 22-04-22 | 23-04-23 | 24-04-24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
10.32
CNY
Average target price
9.3
CNY
Spread / Average Target
-9.88%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -2.09% | 575M | |
| +55.16% | 815B | |
| +44.25% | 654B | |
| -6.42% | 354B | |
| +22.11% | 337B | |
| +10.87% | 302B | |
| +18.45% | 247B | |
| +2.09% | 229B | |
| +13.03% | 219B | |
| +9.70% | 171B |
- Stock Market
- Equities
- 300636 Stock
- Financials Jiangxi Synergy Pharmaceutical Co., Ltd.
